Education
About Us
Working with TipRanks
Follow Us
Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Total Valuation
Forte Biosciences has a market cap or net worth of $44.77M. The enterprise value is ―.
Market Cap$44.77M
Enterprise Value―
Share Statistics
Forte Biosciences has 6,583,382 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,583,382
Owned by Insiders6.51%
Owned by Institutions66.00%
Financial Efficiency
Forte Biosciences’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -91.99%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.81
Return on Invested Capital (ROIC)-91.99%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee0.00
Profits Per Employee-2.25M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Forte Biosciences is -0.82. Forte Biosciences’s PEG ratio is -0.05.
PE Ratio-0.82
PS Ratio0.00
PB Ratio1.62
Price to Fair Value0.73
Price to FCF-1.76
Price to Operating Cash Flow-0.51
PEG Ratio-0.05
Income Statement
In the last 12 months, Forte Biosciences had revenue of 0.00 and earned -31.48M in profits. Earnings per share was -24.92.
Revenue0.00
Gross Profit-9.00K
Operating Income-32.49M
Pretax Income-31.48M
Net Income-31.48M
EBITDA-32.48M
Earnings Per Share (EPS)-24.92
Cash Flow
In the last 12 months, operating cash flow was -29.70M and capital expenditures -23.00K, giving a free cash flow of -29.73M billion.
Operating Cash Flow-29.70M
Free Cash Flow-29.73M
Free Cash Flow per Share-4.52
Dividends & Yields
Forte Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.58
52-Week Price Change-50.29%
50-Day Moving Average6.68
200-Day Moving Average10.29
Relative Strength Index (RSI)59.99
Average Volume (3m)25.01K
Important Dates
Forte Biosciences upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Forte Biosciences as a current ratio of 10.45, with Debt / Equity ratio of 0.00%
Current Ratio10.45
Quick Ratio10.45
Debt to Market Cap0.00
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Forte Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Forte Biosciences EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.49.
EV to Sales0.00
EV to EBITDA-0.43
EV to Free Cash Flow-0.49
EV to Operating Cash Flow-0.49
Balance Sheet
Forte Biosciences has $16.36M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$16.36M billion.
Cash & Marketable Securities$16.36M
Total Debt$0.00
Net Cash-$16.36M
Net Cash Per Share-$2.49
Tangible Book Value Per Share$27.96
Margins
Gross margin is -316.67%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-316.67%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Forte Biosciences is $61.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$61.00
Price Target Upside679.05% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast43.64%